Skip to main content
Fig. 7 | BMC Proceedings

Fig. 7

From: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report

Fig. 7

Summary of the adequate profile of patients considered candidates to switch to the CNIC-Polypill. Note: *Or equivalent doses of the monocomponents. $Use only if the patient does not develop side effects to atorvastatin 80 mg (or equivalent doses of another statin). ACS, acute coronary syndrome; AT, atorvastatin; CV, cardiovascular; EZE, ezetimibe; FDC, fixed-dose combination; LDL-c, low-density lipoprotein cholesterol; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor. Source: Adapted from Grigorian-Shamagian et al. Front Cardiovasc Med. 2021;8:663,361 [12] with permission

Back to article page

BMC Proceedings

ISSN: 1753-6561

Contact us